Publications by authors named "Mitchell Mathis"

Claim this Profile
S
Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration.
Mathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, Hao Zhu, Mehul Mehta

Psychiatr Res Clin Pract· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
Islam R Younis, Mathangi Gopalakrishnan, Mitchell Mathis, Mehul Mehta, Ramana Uppoor

JAMA Psychiatry· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Similarity in Antipsychotic Exposure-Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia.
Shamir N Kalaria, Tiffany R Farchione, Mitchell V Mathis, Mathangi Gopalakrishnan, Islam Younis

J Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
Mathangi Gopalakrishnan, Hao Zhu, Tiffany R Farchione, Mitchell Mathis, Mehul Mehta

J Clin Psychiatry· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials.
Shamir N Kalaria, Hao Zhu, Tiffany R Farchione, Mitchell V Mathis, Mathangi Gopalakrishnan

Clin Pharmacol Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration's Approval of Aripiprazole Tablets With Sensor: Our Perspective.
Daniel J Lee, Tiffany R Farchione, Mitchell V Mathis, Javier Muniz, Brendan M Muoio

J Clin Psychiatry· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.
Liang Li, Yaning Wang, Ramana S Uppoor, Mehul U Mehta, Tiffany Farchione, Mitchell V Mathis

J Pharmacokinet Pharmacodyn· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
Michael C Davis, Brian J Miller, Jasmeet K Kalsi, Thomas Birkner, Mitchell V Mathis

N Engl J Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Mitchell V Mathis, Brendan M Muoio, Paul Andreason, Amy M Avila, Tiffany Farchione

J Clin Psychiatry· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials.
Ni A Khin, Phillip D Kronstein, Peiling Yang, Eiji Ishida, H M James Hung, Mitchell V Mathis

J Clin Psychiatry· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
Jing Zhang, Mitchell V Mathis, Jenn W Sellers, George Kordzakhia, Andre J Jackson

J Clin Psychiatry· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.
Silvana Borges, Yeh-Fong Chen, Thomas P Laughren, Robert Temple, Hiren D Patel, Mitchell Mathis

J Clin Psychiatry· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia.
Islam Rasem Younis, Thomas P Laughren, Yaning Wang, Mitchell Mathis, Jogarao V Gobburu

J Clin Psychopharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
Hobart L Rogers, Atul Bhattaram, Issam Zineh, Jogarao Gobburu, Mitchell Mathis

J Clin Psychiatry· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.
Thomas P Laughren, Jogarao Gobburu, Robert J Temple, Ellis F Unger, Atul Bhattaram, Mitchell Mathis

J Clin Psychiatry· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissociative symptoms from combined treatment with sertraline and trazodone.
Timothy Lacy, Mitchell Mathis

J Neuropsychiatry Clin Neurosci· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis